Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

We hypothesized that GTI-2040, a 20-mer oligonucleotide complementary to the R2 subunit mRNA of ribonucleotide reductase, combined with high dose cytarabine (HiDAC) would result in enhanced cytotoxicity by favoring Ara-CTP DNA incorporation. In a phase I dose escalation trial, adults (≥60 years) wit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Leuk Lymphoma
Glavni autori: Klisovic, Rebecca B., Blum, William, Liu, Zhongfa, Xie, Zhiliang, Kefauver, Cheryl, Huynh, Lenguyen, Zwiebel, James A., Devine, Steven M., Byrd, John C., Grever, Michael R., Chan, Kenneth K., Marcucci, Guido
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298748/
https://ncbi.nlm.nih.gov/pubmed/24015841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.838764
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items